Juvenile Psoriatic Arthritis: A Report from the GRAPPA 2017 Annual Meeting

Devy Zisman, Matthew L. Stoll, Yonatan Butbul Aviel, and Elizabeth D. Mellins

ABSTRACT. Juvenile psoriatic arthritis (JPsA), a subtype of juvenile idiopathic arthritis (JIA), constitutes 5% of JIA. The literature is inconsistent regarding features of JPsA, and physicians debate whether it is a distinct entity within JIA. A biphasic age of onset distribution has been noted. Early-onset disease is characterized by female predominance, small joint involvement, dactylitis, and positive antinuclear antibodies. Late-onset JPsA resembles adult-onset psoriatic arthritis (PsA), with male predominance, psoriasis, enthesitis, and axial disease. Recent studies report improved outcomes, likely due to the widespread use of traditional and biologic disease-modifying antirheumatic drugs. Conflicting HLA associations have been reported in JPsA, but notably both HLA class I and II allele associations are suggested. Similar to PsA cohorts, subjects with JPsA have a lower frequency of a protective inter-leukin 23R allele than controls or other JIA subtypes. Data in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) patient registry suggest the aggressive characteristics of JPsA: 24.6% of children have joint damage 4.6 years after symptom onset. Pediatric and adult PsA classification criteria define different JPsA cohorts within the registry and support a previous suggestion that the International League of Associations for Rheumatology criteria for JPsA may be overly stringent. Increased collaboration between pediatric and adult physicians and comparative research on these clinically related conditions are warranted. (J Rheumatol Suppl. 2018 June;94:11–16; doi:10.3899/jrheum.180131)

Key Indexing Terms: JUVENILE IDIOPATHIC ARTHRITIS   JUVENILE PSORIATIC ARTHRITIS   EPIDEMIOLOGY MANIFESTATIONS   CLASSIFICATION CRITERIA   PSORIATIC ARTHRITIS

History of JPsA
Juvenile psoriatic arthritis (JPsA) is one of 7 subtypes of juvenile idiopathic arthritis (JIA) and constitutes about 5% of JIA1. In 1962, Ansell and Bywaters published the first description of psoriasis in the context of a child with arthritis as part of a case series of what was then called Still disease (now JIA)2. In 1976, Lambert, et al published the first case series of JPsA in a retrospective evaluation of 43 children3. An important observation from this study is that arthritis can precede the development of psoriasis by as many as 15 years. These observations were echoed in a case series of 60 children published by Shore and Ansell in 1982, in which the authors also noted features present early in the disease that predicted the subsequent development of arthritis, including nail pits, an asymmetrical arthritis, and a family history of psoriasis4. The authors called for the development of criteria that would permit JPsA diagnosis without frank psoriasis. This call was answered by Southwood, et al, who proposed a JPsA definition that required arthritis plus either frank psoriasis or at least 2 minor criteria consisting of nail pits, dactylitis, a psoriatic-like rash, or a family history of psoriasis in a first- or second-degree relative5. These criteria, dubbed the Vancouver criteria, were validated in 19966. At the time, under both the American College of Rheumatology and European League Against Rheumatology definitions, the juvenile arthritis umbrella was limited to categories currently referred to as oligoarticular, polyarticular, and systemic; psoriatic arthritis (PsA) and spondylarthropathy (SpA) were considered separate diseases7. This changed in 1997 when Petty, et al convened the International League of Associations for Rheumatology (ILAR) to generate a set of JIA criteria that included the psoriatic and SpA forms and that generated mutually exclusive categories. The first set of criteria was published in 19988, with a second and final version published

From the Department of Rheumatology, Carmel Medical Center; The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; Department of Pediatrics, Ruth Rappaport Children’s Hospital, Rambam Medical Center, Haifa, Israel; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Stanford, California, USA.

As part of the supplement series GRAPPA 2017, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.

D. Zisman, MD, Senior Lecturer, Department of Rheumatology, Carmel Medical Center, and Director of Rheumatology Unit, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; M.L. Stoll, MD, PhD, MSCS, Associate Professor, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; Y. Butbul Aviel, MD, Department of Pediatrics, Ruth Rappaport Children’s Hospital, Rambam Medical Center, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology; E.D. Mellins, MD, Professor, Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University.

Address correspondence to Dr. D. Zisman, Department of Rheumatology, Carmel Medical Center, 7 Michal St., Haifa 34362, Israel. E-mail: devyzisman@gmail.com
in 2004\textsuperscript{9}. The current diagnostic criteria are summarized in Table 1, although it has been suggested that the ILAR criteria are overly stringent and result in missed JPsA diagnoses\textsuperscript{10}.

**Clinical Features of JPsA**

Clinically, JPsA is a heterogeneous condition that is generally an asymmetrical arthritis, which frequently extends from oligo- to polyarticular\textsuperscript{6,11}. Both small and large joint involvement are present in the majority of patients\textsuperscript{5,12,13}, with axial disease seen in up to 25\%\textsuperscript{4} and dactylitis in 15–50\%\textsuperscript{4,5,12}. Extraarticular features are common. The initial descriptions required psoriasis as an entry criterion, which by definition caused it to be present in 100\% of cases\textsuperscript{3,4}. Descriptions published since the Vancouver criteria show psoriasis to be present in 25–60\% of cases, with the remainder of cases diagnosed on the basis of minor criteria\textsuperscript{5,12,13}. As noted above, psoriasis develops after the onset of arthritis in about 50\% of cases\textsuperscript{13}, underscoring the value of the minor criteria in the diagnosis of this disorder. Additional extraarticular features include nail pits in 50–80\% of cases\textsuperscript{6,14}, uveitis in 8–15\%\textsuperscript{3,5,6,14}, and inflammatory bowel disease (IBD) in at most 1\%\textsuperscript{15}. Notably, most descriptions of uveitis in children with JPsA are consistent with the chronic uveitis characteristic of oligo- and polyarticular JIA, rather than the acute anterior uveitis associated with HLA-B27+ SpA\textsuperscript{5,6,12}. Laboratory findings are generally unremarkable, although the antinuclear antibody (ANA) test may be positive in at least 50\% of cases\textsuperscript{5,6,16}. Radiographic studies can reveal a variety of abnormalities, including erosive disease, joint space narrowing, and sacroiliitis\textsuperscript{3,11,17}. JPsA’s outcome has improved considerably over the years following the introduction and widespread use of modern therapeutics. Initial studies revealed functional class III or IV outcomes in nearly one-third of patients\textsuperscript{6,11}, while more recently published descriptions have shown remission in over 50\% of subjects\textsuperscript{16,18,19}. There is very little treatment data specifically geared toward JPsA. The German BIKER registry included 127 children with JPsA who were treated with etanercept. This registry reported response rates and a safety profile similar to other JIA categories\textsuperscript{20}.

**Disagreements about JPsA**

JPsA has provided pediatric rheumatologists with debate topics for many years. The 2 main topics on which there is no consensus are (1) Does JPsA constitute a homogeneous group of patients? and (2) Does JPsA exist as a distinct entity within JIA?

**Does JPsA constitute a homogeneous group of patients?**

Many old and recent studies have shown a biphasic age of onset distribution in children with JPsA\textsuperscript{3,5,15,16}, directing the clinical manifestations. Children with early-onset disease tend to have similar features compared to other children with early-onset JIA, including increased predominance in females, positive ANA, and chronic uveitis; whereas children with onset older in life tend to have features suggestive of SpA, including axial disease, enthesitis, and less small joint disease\textsuperscript{15,16,21}. Somewhat unexpectedly, dactylitis appears to be largely associated with early-onset disease, despite its association with adult PsA, as well\textsuperscript{13,15}.

Butbul Aviel, \textit{et al} also showed that JPsA is a heterogeneous condition based upon clinical phenotype. Butbul Aviel, \textit{et al} retrospectively evaluated 122 patients with JPsA, dividing their cohort into 4 main groups according to clinical manifestations that were comparable to the JIA definition suggested by the ILAR criteria: (1) oligoarticular (55\%); (2) rheumatoid factor (RF)–negative polyarticular (29\%); (3) RF-positive polyarticular (3\%); (4) enthesis-related arthritis (ERA; 13\%). Of the 65 patients with oligoarticular onset, 32\% eventually developed polyarticular disease\textsuperscript{22}. The study found differences in the course, as well as the outcome, of the disease between the groups. The ERA group tended to be older and to have sacroiliac and hip involvement, whereas the polyarticular group had involvement of small joints of the hand, as well as wrist involvement. They also found that the patients in the polyarticular group had the worst outcomes because they took longer to achieve remission and were more likely to have contractures\textsuperscript{22}. Therefore, JPsA is clearly a heterogeneous disorder, resembling in part the heterogeneity that has long been identified in its adult counterpart\textsuperscript{23}.

**Does JPsA exist as a distinct entity within JIA?**

Another disputed issue is whether JPsA exists as a distinct entity within JIA. Only a few studies have addressed these uncertainties. Most of the studies have focused on comparing clinical data between groups, but later, new genetics data were published. Stoll, \textit{et al} compared patients with JPsA and JIA with oligoarticular onset in the first 6 months and found that the JPsA group were older, more likely to have involvement of small joints and wrists, and more likely to extend to a polyarticular course\textsuperscript{24}. Even when the comparison...
was limited to children with age of onset under 5 years, similar clinical differences in joint distribution were observed. These data corroborated the study by Huemer, et al, which showed increased small joint and wrist disease among patients with oligoarticular JPsA as compared to oligoarticular JIA. They were also corroborated by Ravelli, et al, whose findings showed that even ANA+ patients with JPsA tended to be older at disease presentation than the rest of their ANA+ JIA counterparts.

Contradictory data have been published. Butbul Aviel, et al used a case control study to compare 53 children with JPsA to 53 children with JIA; 32 with oligoarticular and 21 with polyarticular onset. Patients were matched by sex, age, date of diagnosis, and articular-onset pattern. There were no differences between the groups in the percentage of patients in the oligoarticular groups who extended to a polyarticular course or in the type of joint involvement. There were limited data on outcome, which suggests that time to first inactive disease with or without treatment was similar in both groups. Therefore, it remains unclear whether there are clinical differences between oligoarticular/polyarticular JIA and oligoarticular/polyarticular JPsA.

Late-onset JPsA, however, appears to be substantially different from ERA. Compared to their counterparts with ERA, children with JPsA are less likely to carry the HLA-B27 marker, less likely to have sacroilitis, less likely to have hip involvement, and as noted above more likely to have chronic, rather than acute, uveitis. Additionally, psoriatic features such as psoriasis and dactylitis were protective against the development of sacroilitis. Hip involvement was a risk factor. Therefore, JPsA is a heterogeneous condition in which children with early-onset are generally similar to children with early-onset JIA, yet children with late-onset disease are clearly distinct from their counterparts with ERA, but do resemble early-onset PsA.

We have likely gleaned as much information as we can from clinical studies. The next step is to use genetics to better delineate the differences between JIA and JPsA, as well as to define correspondences with adult inflammatory arthritides.

Immunogenetics of JPsA

Analysis of JPsA genetics has the potential to provide clues to the basis of the earlier onset of this disease compared to PsA and to suggest immune mechanisms in JPsA. There are several strategies for identifying JPsA genetic risk factors: testing for associations with HLA alleles, testing candidate genes identified by PsA genome-wide association studies (GWAS), and testing genes that cause monogenic disorders with phenotypic overlap with JPsA.

The first study of HLA association with JPsA, published by Ansell, et al in 1993 compared a cohort of 70 children diagnosed with JPsA to 310 controls, all from the United Kingdom. Of the 69 subjects with JPsA, 47 had a strong family history of psoriasis. A statistically significant association with HLA-B27 was observed. In a UK study that examined HLA class II associations across ILAR JIA subtypes, 37 patients with JPsA were analyzed. The DRB1*01/DQA1*0101/DQB1*0501 haplotype conferred risk with an OR of 3.8 (95% CI 1.7–9.8). The most recent study by Hinks, et al used dense single-nucleotide polymorphism (SNP) typing of the HLA region to study 5043 JIA cases, 112 JPsA cases, and 14,390 controls. No JPsA associations reached genome-wide significance (p < 5 × 10^-8), but the following associations were observed: DRB1*08 (p = 0.0003); DQA1*0401 (p = 0.0001); DQB1*0402 (p = 0.0008); HLA-B27 (p = 0.003); and HLA-C*0602 (p = 0.008). Age-stratified analysis was not reported. These results could reflect 2 subtypes of JPsA or independent genetic associations. Interestingly, the class I associations overlap with PsA associations, and the B27 and C*0602 alleles are associated with different phenotypes in PsA subjects.

Overall, to date, HLA association studies in JPsA found varied results, but do suggest both HLA class I and class II associations. Notably, a study of HLA associations in JIA from Murray, et al showed that having more HLA risk alleles predisposed the earlier onset of JIA.

Several mechanisms underlying HLA-B27 associations with rheumatic diseases have been hypothesized. The earliest hypothesis pertained to the ability of HLA alleles to present arthritogenic peptides. However, additional hypotheses have emerged in recent years. One model emphasizes the propensity of HLA-B27 to misfold, causing endoplasmic reticulum stress; another emphasizes the recognition of B27 dimers by KIR3DL2 receptors on CD4+ Th17 cells. For the associated DQ alleles, impaired interactions with accessory molecules that regulate peptide loading of HLA class II molecules have been observed and hypothesized to be a basis for presentation of cryptic epitopes of self-proteins, which break immune tolerance. However, specific, mechanistic contributions of associated HLA class I or class II alleles to JPsA pathogenesis, in particular, have not yet been identified.

Using the approach of testing genetic associations observed for PsA, Hinks, et al studied 1244 JIA cases, 93 JPsA cases, and 5200 controls. The study found a negative association between JPsA and an SNP linked to the minor, protective allele of interleukin 23R (IL-23R), the IL-23 receptor gene. This association was not observed in JIA overall or in other ILAR JIA subtypes. Testing the role of IL-23 in JPsA using pharmacologic blockade of the pathway has not been done to date, and further investigation is warranted.

The approach of testing genes that cause monogenic disorders with some phenotypic overlap with JPsA was used by Day, et al. Genes causing hereditary periodic fever syndromes were tested in 950 UK white JIA cases, including 67 JPsA cases and 728 controls. The genes tested were MEFV.
Lessons from a Large Database of Children with JPsA

The CARRA registry contains disease-specific cohorts as defined by treating physicians from over 100 sites in the United States and Canada and collected data on 9450 children with pediatric rheumatic diseases between May 2010 and December 2013. Data from this cohort were retrospectively analyzed in light of the current understanding of PsA reflected in the pediatric and adult rheumatology literature. The JPsA cohort of 361 children (4.9%) in this registry is line with published data on the prevalence of this JIA subtype. The majority were white (93.9%) and non-Hispanic (91.7%), with a female predominance (62%). Average age at symptom onset was 8.34 ± 4.57 years, with a delay of 1.04 ± 1.46 years from the first symptom to the first pediatric rheumatology appointment. The most common musculoskeletal manifestation was polyarthritis (55.3%), followed by oligoarthritis (44.7%), enthesitis (32.7%), dactylitis (29.7%), and sacroiliitis (16.7%). Dermatologic manifestations included rash in 66.8% and nail pitting in 37.5%, lower prevalence than those reported for PsA. A possible explanation is that, in contrast to adult PsA, the articular manifestations precede skin manifestations in JPsA, and disease-modifying antirheumatic drugs (DMARD) may obscure their appearance. The prevalence of ANA (46.2%) and RF (4.7%) positivity in the cohort is in the range reported in other JPsA studies and in studies of adult PsA. Radiographic evidence of joint damage in 24.6% of the patients, an average of 4.6 years from the time of symptom onset, despite treatment with conventional and biologic DMARD (52.9%) is similar to the Southwood, et al findings in 1989 before the use of biological therapies. These data were confirmed in a report describing radiographic damage in patients with PsA that underscores the potential of psoriatic joint disease, in general, to cause joint damage and the importance of early diagnosis and therapy.

Similar to PsA, the JPsA cohort exhibited asymptomatic axial involvement and no correlation between the presence of HLA-B27 and radiographic findings of sacroilitis or the presence of clinical sacroilitis. At enrollment, half of the patients were treated with glucocorticosteroids (52.1%) and biological DMARD (52.9%), consisting mainly of antitumor necrosis factor-α agents. Conventional DMARD, the most common being methotrexate, were prescribed to 81.4% of the cohort.

The objective improvement in the clinical variables, including arthritis, psoriasis, nail pitting, dactylitis, and enthesitis, was not accompanied by improvement in scores on health-related questionnaires, highlighting JPsA’s potential, as in PsA, to cause disability beyond the objective measurable variables.

The biphasic age of onset observed in the CARRA cohort, in line with previous JPsA studies, may suggest an interesting phenotype of disease presentation according to the age of symptom onset, probably influenced by genetic factors. JPsA manifested in early childhood, predominantly as a disease of females with peripheral arthritis, followed by presentation of late-onset JPsA and early-onset PsA in males with SpA features, and a later presentation with a tendency to peripheral arthritis.

The recent conception of PsA in adults, in the spectrum of SpA including enthesitis and inflammatory back pain, is the main difference between the adult classification criteria for PsA (CASPAR criteria) and the ILAR classification criteria for JIA. This concept was partially implemented by pediatric rheumatologists in the CARRA registry. In the JPsA cohort, 105 children who did not fulfill the ILAR criteria, but who were diagnosed by their treating physicians, exhibited fewer typical manifestations, such as dactylitis, nail pitting, and psoriasis. On the other hand, 52 additional patients who fulfilled CASPAR criteria for PsA but who were not classified in that way by their pediatric rheumatologists were identified in the entire JIA cohort. Those patients had less psoriasis but more features of SpA, such as enthesitis, inflammatory back pain, IBD, and uveitis. The evidence of asymptomatic enthesitis in patients with JPsA is additional support for this concept.

Awareness of these differences in classification is important to ensure that young adults with JPsA are successfully transferred from pediatric to adult care and that their evaluation and treatment are directed by an appropriate diagnosis, particularly as we learn more about the pathogenesis of JPsA.

To overcome the gaps, increased collaboration between pediatric and adult dermatologists and rheumatologists is needed, such as establishing a study group in the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.
Table 2. Comparison between ILAR criteria for JPsA and CASPAR criteria for PsA.

<table>
<thead>
<tr>
<th>Variables</th>
<th>ILAR Criteria(^9)</th>
<th>CASPAR Criteria(^7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rheumatic manifestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>Favors diagnosis of ERA</td>
<td>X</td>
</tr>
<tr>
<td>Axial spine</td>
<td>Favors diagnosis of ERA</td>
<td>X</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Skin manifestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>History of psoriasis</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Family history</td>
<td>X first-degree relatives only</td>
<td>X first- or second-degree relatives</td>
</tr>
<tr>
<td>Nail involvement</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Laboratory results</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF positivity</td>
<td>Exclusion if 2 tests positive 3 mos apart</td>
<td>Exclusion</td>
</tr>
<tr>
<td><strong>Radiologic manifestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetics (HLA-B27)</td>
<td>Exclusion in male, if arthritis started after the age of 6 weeks and psoriasis or at least 2 of dactylitis, nail involvement, history of psoriasis</td>
<td>A patient must have inflammatory articular disease (joint, spine, or enthesal) with 3 points from the 5 categories: skin, nail, RF test, dactylitis, radiographic</td>
</tr>
<tr>
<td>Requirements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclusions</td>
<td>Arthritis in an HLA-B27—positive male beginning after the sixth birthday. AS, ERA, sacroiliitis with IBD, Reiter syndrome or acute anterior uveitis, or a history of 1 of these disorders in a first-degree relative: (1) the presence of IgM RF on at least 2 occasions at least 3 mos apart; (2) the presence of systemic JIA in the patient.</td>
<td>None</td>
</tr>
<tr>
<td><strong>Sensitivity</strong></td>
<td></td>
<td>91.4%</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td></td>
<td>98.7%</td>
</tr>
</tbody>
</table>

ILAR: International League of Associations for Rheumatology; PsA: psoriatic arthritis; JPsA: juvenile PsA; CASPAR: ClASsification for Psoriatic ARthritis criteria; ERA: enthesitis-related arthritis; RF: rheumatoid factor; AS: ankylosing spondylitis; IBD: inflammatory bowel disease; IgM: immunoglobulin M; JIA: juvenile idiopathic arthritis.

Table 2. Comparison between ILAR criteria for JPsA and CASPAR criteria for PsA.